REFERENCES
- National Institute of Infectious Diseases. [in Japanese] Infect
Agents Surveil Report. 2019; 40: 192-194.
- The Ministry of Health, Labour and Welfare. The treatment guidelines
for adults of novel influenza. https://www.mhlw.go.jp/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/infulenza/dl/guideline.pdf Accessed June 6, 2020.
- The Japanese Respiratory Society. The influenza internet surveillance
system. [in Japanese] https://www.jrs.or.jp/iis/ Accessed June 6, 2020.
- The Japanese Respiratory Society. The JRS guidelines for management of
pneumonia in adults. [in Japanese] The Japanese Respiratory
Society, Tokyo, 2017.
- Abdel-Hady, Balushi, RM, Abri BA, et al. Estimating the burden of
influenza-associated hospitalization and death in Oman (2012-2015).
Influenza Other Respir Viruses 2018; 15: 146-152.
- Palekar RS, Rolfes MA, Arriola CS, et al. Burden of
influenza-associated respiratory hospitalizations in Americas,
2010-2015. PloS One 2019 Sep 6; 14(9): 0221479. doi:
10.1371/journal.pone.0221479.
- Ng Y, Chua LAV, Ma S, Lee VJM. Estimates of influenza-associated
hospitalizations in tropical Singapore, 2010-2017: higher burden
estimated in more recent years. Influenza Other Respir Viruses 2019;
13: 574-581.
- Ao T, McCracken JP, Lopez MR, et al. Hospitalization nd death among
patients with influenza, Guatemala, 2008-2012. BMC Public Health 2019
May 10; 19 (Suppl 3):463. doi: 10.1186/s12889-019-6781-6.
- Pivette M, Nicolay N, de Lauzun V, Hubert B. Characteristics of
hospitalization with an influenza diagnosis, France, 2012-2013 to
2016-2017 influenza seasons. Influenza Other Respir Viruses 2020; 14:
340-348.
- Moa AM, Muscatello DJ, Turner RM, Maclntyre CR. Estimated
hospitalizations attributable to seasonal and pandemic influenza in
Australia: 2001-2013. PloS One 2020 Apr 13; 15(4):e0230705. doi:
10.1371/journal.pone.0230705.
- Yokomichi H, Mochizuki M, Lee JJ, Kojima R, Yokoyama T, Yamagata Z.
Incidence of hospitalization for severe complications of influenza
virus infection in Japanese patients between 2012 and 2016: a
cross-sectional study using routinely collected administrative data.
BMJ Open 2019 Jan 17; 9(1):e024687. doi: 10.1136/bmjopen-2018-024687.
- Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated
hospitalizations in the United States. JAMA 2004; 292: 1333-1340.
- Shrestha SS, Swerdlow DL, Borse RH, et al. Estimating the burden of
2009 pandemic influenza A (H1N1) in the United States (April
2009-April 2010). Clin Infect Dis 2011; 52: S75-S82.
- Louie JK, Acosta M, Winter K, et al. Factors associated with death or
hospitalization due to pandemic 2009 influenza A(H1N1) infection in
California. JAMA 2009; 302: 1896-1902.
- Maruyama T, Fujisawa T, Suga s, et al. Outcome and prognostic features
of patients with influenza requiring hospitalization and receiving
early antiviral therapy. Chest 2016; 149: 526-534.
- Gadsby NJ, Russell CD, McHugh MP, et al. Comprehensive molecular
testing for respiratory pathogens in community-acquired pneumonia.
Clin Infect Dis 2016; 62: 817-823.
- Klein EY, Monteforte B, Gupta A, et al. The frequency of influenza and
bacterial coinfection: a systematic review and meta-analysis.
Influenza Other Respir Viruses 2016; 10: 394-403.
- Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice
guidelines by the Infectious Diseases Society of America: 2018 update
on diagnosis, treatment, chemoprophylaxis, and institutional outbreak
management of seasonal influenza. Clin Infect Dis 2019; 68: e1-e47.
- The Ministry of Health, Labour and Welfare. Age distribution of fatal
cases dueb to 2009 pandemic influenza A (H1N1) in Japan https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou04/rireki/100331-03.html Accessed June 6, 2020.
- Sugaya N, Shinjoh M, Mitamura K, et al. Comparison of the clinical
effectiveness of oseltamivir and zanamivir against influenza in
children. Clin Infect Dis 2008; 47: 339-345.
- Sugaya N. Widespread use of neuraminidase inhibitors in Japan. J
Infect Chemother 2011; 17: 595-601.
- Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir marboxil for
uncomplicated influenza in adults and adolescents. 2018; 379: 913-923.
- Ison MG, Postmouth S, Yoshida Y, et al. Early treatment with baloxavir
marboxil in high-risk adolescent and adult outpatients with
uncomplicated influenza (CAPSTONE-2): a randomised,
placebo-controlled, phase 3 trial. Lancet Infect Dis 2020 Jun 8;
S1473-3099(20)30004-9. doi: 10.1016/S1473-3099(20)30004-9.
- Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-emergent influenza
variant viruses with reduced baloxavir susceptibility: impact on
clinical and virologic outcomes in uncomplicated influenza. J Infect
Dis 2020; 221: 346-355.
- Yoshimura Y, Sasaki H, Horiuchi H, et al. Early combination treatment
with baloxavir and peramivir for hospitalized adults with influenza A
in Yokohama, Japan. Eur J Clin Microbiol Infect Dis 2020 Apr 14. doi:
10.1007/s10096-020-03888-7.
- Schanzer DL, Langley JM, Tam TW. Co-morbidities associated with
influenza-attributed mortality, 1994-2000, Canada. Vaccine 2008; 26:
4697-4703.
- Lee N, Choi KW, Chan PK, et al. Outcomes of adults hospitalised with
severe influenza. Thorax 2010; 65: 510-515.
- Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel
virus: obesity and 2009 pandemic influenza A (H1N1). Clin Infect Dis
2011; 52: 301-312.
- Moser JS, Galindo-Fraga A, Ortiz-Hernández AA, et al. Underweight,
overweight, and obesity as independent risk factors for
hospitalization in adults and children from influenza and other
respiratory viruses. Influenza Other Respir Viruses 2019; 13: 3-9.